Reusable Single Cell for Iterative Epigenomic Analyses
February 11th, 2022
1.5K views
The present protocol describes a single-cell method for iterative epigenomic analyses using a reusable single cell. The reusable single cell allows analyses of multiple epigenetic marks in the same single cell and statistical validation of the results.
Overview
This protocol outlines a novel single-cell method for iterative epigenomic analyses using reusable single cells. This approach enables the analysis of multiple epigenetic marks within the same cell, facilitating statistical validation of results.
Key Study Components
Area of Science
- Epigenomics
- Cell Biology
- Genetics
Background
- Current single-cell epigenome analysis methods do not allow for reanalysis of the same cells.
- This method addresses limitations in patient cell availability for epigenetic studies.
- Specific antibodies for epigenetic marks are required for this technique.
- Long-term storage of reusable single cells is possible for ongoing epigenomic testing.
Purpose of Study
- To develop a method that allows for multiple analyses of the same single cell.
- To enhance the understanding of gene expression regulation.
- To facilitate the design of epigenetic therapies.
Methods Used
- Reusable single-cell technology for epigenomic analysis.
- Long-term storage techniques for single cells.
- Analysis of various epigenetic marks and transcription factors.
- Statistical validation of results from multiple analyses.
Main Results
- Demonstrated the feasibility of reanalyzing the same single cells.
- Showed the ability to analyze multiple epigenetic marks simultaneously.
- Provided insights into the regulation of gene expression.
- Highlighted the potential for improved epigenetic therapy design.
Conclusions
- The reusable single-cell method significantly advances epigenomic research.
- This technique is particularly beneficial when patient cells are limited.
- Future studies can leverage this method for deeper insights into epigenetic mechanisms.
Frequently Asked Questions
What is the main advantage of using reusable single cells?
The main advantage is the ability to reanalyze the same single cells multiple times, allowing for comprehensive epigenomic studies.
How does this method contribute to epigenetic therapy?
It enables detailed analysis of limited patient cells, aiding in the design of targeted epigenetic therapies.
What types of analyses can be performed with this method?
The method allows for the analysis of various epigenetic marks and transcription factors in a single cell.
Are specific antibodies required for this technique?
Yes, specific antibodies for the epigenetic marks being studied are necessary.
Can this method be applied to other areas of research?
Yes, it can be applied to studies involving gene expression regulation and other epigenomic systems.
Executive Industry Relevance
Iterative epigenomic analysis using reusable single cells addresses a critical bottleneck in single-cell profiling by enabling multiple rounds of data collection from rare or precious samples. This approach increases predictive confidence in epigenetic target validation and supports robust mechanistic de-risking at early discovery and translational inflection points. The method enhances portfolio value by maximizing data density from limited patient-derived or disease-relevant cells.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables repeated interrogation of epigenetic marks in the same cell, reducing biological noise.
- Supports functional target validation by allowing direct comparison of multiple modifications within a single cell.
- Improves predictive confidence for pathway analysis and mechanistic de-risking.
Screening & Assay Development
- Facilitates preparation of validated single-cell systems for downstream multi-omic workflows.
- Enables assay standardization and reproducibility by controlling for cell-to-cell variability.
- Provides quantitative outputs for reliable compound or antibody screening in epigenetic contexts.
Translational & Preclinical Research
- Aligns with disease-relevant systems by maximizing data from rare patient samples.
- Supports continuity from discovery through preclinical validation by enabling longitudinal single-cell analysis.
- Reduces risk in translational biomarker development by increasing within-cell data density.
Pipeline & Workflow Integration
This method integrates into the discovery-to-preclinical continuum by enabling iterative hypothesis testing and multi-marker profiling within the same single cell.
- Discovery Biology: Supports hypothesis testing and pathway clarification by allowing repeated epigenetic measurements in individual cells.
- Screening: Provides assay readiness and reproducibility through standardized single-cell reuse.
- Analytics: Delivers quantitative readouts and statistical outputs for comparing antibody and control IgG signals within the same cell.
- Translational Research: Enables preclinical continuity by storing and reusing rare or patient-derived cells for extended analysis.
- Enterprise Reuse: Establishes a reusable single-cell platform for multi-omic and iterative epigenetic studies across programs.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence and reduces mechanistic ambiguity in epigenetic target validation.
- Operational Value: Standardizes workflows and enhances reproducibility by minimizing inter-cell variability.
- Strategic Value: Enables better go/no-go decisions and capital efficiency by extracting maximal data from limited samples.
- Portfolio Impact: Supports risk-adjusted prioritization and advancement of epigenetic targets and biomarkers.
Implementation Considerations
- Requires expertise in single-cell handling, epigenomic assays, and proximity ligation techniques.
- Demands access to sequencing platforms and analytical infrastructure for multi-marker data integration.
- Necessitates cross-team standardization for sample preparation and data analysis protocols.
- Adaptation may be needed for different cell types or disease models based on antibody availability.
- Long-term storage and reuse protocols must be validated for each application to ensure data integrity.
Biopharma FAQs
Why does null hypothesis testing matter for iterative single-cell epigenomic analysis?
Null hypothesis testing enables rigorous differentiation between true epigenetic signals and experimental background by comparing antibody and control IgG data within the same cell, increasing confidence in target validation decisions.
How does independent variable isolation fit the reusable single-cell workflow?
Isolating variables such as specific epigenetic marks in the same cell allows direct assessment of multiple modifications, reducing confounding factors and supporting mechanistic de-risking in early discovery pipelines.
What do quantitative dependent variable measurements enable in this protocol?
Quantitative measurements of antibody and control signals within a single cell provide robust statistical outputs, facilitating comparison of epigenetic modifications and supporting reliable assay development.
Why are replication requirements critical for cross-functional collaboration in single-cell epigenomics?
Replication using the same reusable single cell ensures data consistency and reproducibility, enabling cross-team validation and integration of results across discovery and translational research groups.
Which statistical analysis capabilities are required before implementing iterative single-cell epigenomic assays?
Robust statistical analysis is needed to compare antibody and control IgG signals, assess overlap with bulk ChIP-seq data, and validate sensitivity and precision thresholds for epigenetic mark detection.
Chapters in this video
0:05
Introduction
1:32
Preparation of Reusable Single Cells: Manual Version
3:09
Random Primer Annealing and Extension
4:09
Antibody Binding and Proximity Ligation of Antibody Probe and Proximally Extended Random Primer
5:25
Full Extension of the 1st Random Primer and Multiple Displacement Amplification
7:32
Results: Single Cell Multiepigenomic Analysis
9:26
Conclusion
